Market Newsdesk

Glu Files Patent Infringement Lawsuit Against Reworks Oy, Developer of Redecor

SAN FRANCISCO–(BUSINESS WIRE)–
Glu Mobile Inc. (NASDAQ: GLUU), a leading developer and publisher of mobile games, today filed a lawsuit in federal court alleging that Reworks Oy infringes a Glu patent relating to systems and methods for providing competitive scene completion in a mobile gaming application—a core feature of Glu’s widely-popular Design Home mobile game.

Design Home is a free-to-play mobile game that brings design dreams to life with a social and competitive twist. Players have the opportunity to decorate living rooms, dining rooms, bedrooms and outdoor spaces with thousands of furniture and home décor items from today’s leading brands in a visually stunning 3D experience.

Glu owns all rights and IP associated with Design Home as a result of its acquisition of Crowdstar in 2016. Glu has invested substantial resources in Design Home, which has enabled the game to captivate a global audience of highly creative players who have downloaded Design Home more than 90 million times. The game recently surpassed a half billion dollars in lifetime bookings, demonstrating its leadership in the mobile casual games space.

The lawsuit alleges that Reworks’ Redecor mobile game infringes at least one claim of U.S. Patent No. 10,504,297. Glu is pursuing a judgment finding that Reworks has infringed Glu’s patent and seeks injunctive relief, as well as monetary damages for past and ongoing infringement.

“Glu is not a litigious company but given this clear patent infringement by Reworks, we have a responsibility to file this lawsuit—we must protect the value of our innovation and intellectual property,” said Glu Vice President and General Counsel, Scott Leichtner.

About Glu Mobile

Glu Mobile (NASDAQ: GLUU) is a leading developer and publisher of mobile games. Founded in 2001, Glu is headquartered in San Francisco with additional locations in Foster City, Toronto and Hyderabad. With a history spanning over a decade, Glu’s culture is rooted in taking smart risks and fostering creativity to deliver world-class interactive experiences for our players. Glu’s diverse portfolio features top-grossing and award-winning original and licensed IP titles including, Covet Fashion, Deer Hunter, Design Home, Diner DASH Adventures, Disney Sorcerer’s Arena, Kim Kardashian: Hollywood and MLB Tap Sports Baseball available worldwide on various platforms including the App Store and Google Play. For more information, visit www.glu.com or follow Glu on Twitter, Facebook and Instagram.

Crowdstar, Covet Fashion, Deer Hunter, Design Home, Diner DASH, Tap Sports, Glu and Glu Mobile are trademarks of Glu Mobile Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006090/en/

Investor Relations:

Bob Jones / Taylor Krafchik

Ellipsis

[email protected]

646-776-0886

Media:

Claudia Oropeza

[email protected]

415-800-6378

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Electronic Games Mobile Entertainment Technology Entertainment Software

MEDIA:

Posted on December 17, 2020 4:08 pm

Orion Group Holdings, Inc. Announces Contract Awards of Approximately $20 Million

Orion Group Holdings, Inc. Announces Contract Awards of Approximately $20 Million

HOUSTON–(BUSINESS WIRE)–
Orion Group Holdings, Inc. (NYSE: ORN) (the “Company”) a leading specialty construction company, today announced contract awards totaling approximately $20 million.

The Company’s Marine segment has been awarded two contracts for projects in Florida. The first project, valued at approximately $10.7 million, is for the City of St. Petersburg, Florida, and requires the demolition, removal and replacement of the 40^th Avenue NE Bridge spanning Placido Bayou with a new dual carriageway concrete structure. The work is expected to begin in the first quarter of 2021 and will take approximately 10 months to complete.

The second contract is with Brantley Construction Services, LLC, to support a project for NAVFAC Southeast at Naval Station Mayport. The work, valued at approximately $10 million, involves the replacement of a 550-foot wharf quay wall with a new steel sheet pile bulkhead. Activity on the contract will begin immediately and is expected to be completed by the end of 2021.

“These two projects not only add backlog for our Marine segment but represent the type of work that we are well suited to perform. We look forward to starting work on these jobs and safely delivering long-lasting and high-quality structures to our clients,” said Mark Stauffer, Orion’s President and Chief Executive Officer.

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on February 28, 2020, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006062/en/

Orion Group Holdings Inc.

Francis Okoniewski, Vice President Investor Relations

(346) 616-4138

[email protected]

www.oriongroupholdingsinc.com

Robert Tabb, Vice President & CFO

(713) 852-6500

www.oriongroupholdingsinc.com

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property Urban Planning

MEDIA:

Logo

Timothy Mullany to Join Jack in the Box Inc. as New Chief Financial Officer

SAN DIEGO–(BUSINESS WIRE)–
Jack in the Box Inc. (NASDAQ: JACK) announced today that Timothy Mullany will join the company as Executive Vice President and Chief Financial Officer, effective January 18, 2021.

Mullany is a well-rounded finance leader with more than 20 years of experience in the restaurant industry, as well as hyper-growth concepts, both public and private. Most recently, Mullany served as Chief Financial Officer at VASA Fitness where he was responsible for leading the finance and accounting team plus developing and executing company growth strategies, including site acquisition and market entry development.

“We are excited for the addition of Tim to the Jack in the Box team. He has demonstrated strong financial leadership while supporting growing businesses in the restaurant industry. We are confident in his executive leadership ability to help continue the momentum being experienced at Jack in the Box,” said Darin Harris, Chief Executive Officer.

Previously, Tim was Chief Financial Officer at RAVE Restaurant Group, Inc. (NASDAQCM: RAVE) where he helped scale Pie Five Pizza from a regional start up into one of the nation’s leading fast casual pizza concepts. Prior to that he held additional Chief Financial Officer roles at Restaurants Unlimited Inc. and Consumer Capital Partners, franchisor and operator of the Smashburger and Quiznos brands. Earlier in his career he also led the financial functions of Global Portfolio Advisors Ltd, its affiliate Outpost International, and Sea Research Foundation, along with founding Mystic Entertainment Company. His career began with positions in private equity and investment banking at J.P. Morgan and Bank of America, respectively, and KPMG LLP. Tim holds an MBA from Columbia Business School and a BS from Villanova University.

“I am thrilled to join Darin and the Jack in the Box team. I have been a longtime fan of the brand and with my experience in growing businesses, and specifically my knowledge within the restaurant industry, I look forward to leading the organization as it embarks on an accelerated growth strategy, in partnership with our employees and franchisees,” said Mullany.

Taysha Gene Therapies Announces New cGMP Gene Therapy Manufacturing Facility

Approximately 187,000-square-foot facility located in Durham, NC designed to support preclinical through commercial cGMP manufacturing for Taysha’s broad pipeline of gene therapies

Multiple production suites with total capacity of 2,000 liters expected to be production-ready by 2023

Taysha to invest $75 million and create approximately 200 jobs over two and a half years; Company to receive up to $9.4 million in state and local incentives

DALLAS–(BUSINESS WIRE)–
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced that it has entered into a lease agreement to occupy and configure an approximately 187,000-square-foot commercial-scale current Good Manufacturing Practices (cGMP) manufacturing facility in Durham, North Carolina for preclinical, clinical and commercial production of its gene therapy pipeline. The Company will invest $75 million and create approximately 200 jobs over a two-and-a-half-year period to build out development, analytical, manufacturing and quality control testing capability for its broad portfolio of gene therapies.

Multiple production suites, which are expected to be fully commissioned by 2023, will allow production according to the U.S. Food and Drug Administration guidelines. The facility will establish 2,000 liters of capacity and will be designed to support all aspects of scalable manufacturing of gene therapy material for Taysha’s pipeline and to meet the foreseeable clinical and commercial demand. This internal capability will bolster the current capacity from Taysha’s existing manufacturing collaborations with UT Southwestern’s Gene Therapy Program and Catalent. The investment in the facility is part of the Company’s comprehensive three-pillar manufacturing strategy to meet the supply demands of multiple concurrent clinical programs emerging from its gene therapy pipeline as the Company anticipates having four open Investigational New Drug applications in 2021.

“This state-of-the-art facility is an integral part of our manufacturing strategy that will enable us to rapidly and efficiently deliver potentially transformative treatments to patients with monogenic CNS diseases,” said RA Session II, President, Founder and CEO of Taysha. “With our outstanding team of experts leading the charge, we expect this facility will serve as a center of excellence for gene therapy development, from preclinical studies through commercialization, and will further our leadership position in gene therapy as well as support our next phase of growth.”

“Given the potential demand of our robust portfolio, establishing internal capacity using our HEK293 suspension process is a key addition to our manufacturing supply chain, allowing us to drive efficiencies and scalability while potentially reducing the time to bring our gene therapy solutions to patients,” said Frederick Porter, Ph.D., Chief Technical Officer of Taysha. “We anticipate this facility will complement existing capabilities and secure our long-term supply chain, which aligns well with our strategic goals. We are excited to expand our footprint in North Carolina, home to a thriving gene therapy ecosystem with a talented and seasoned workforce with deep gene therapy manufacturing expertise.”

Taysha’s expansion in North Carolina will be facilitated by state and local incentives totaling up to $9.4 million. Specifically, a Job Development Investment Grant (JDIG), approved by the state’s Economic Investment Committee earlier today, will provide Taysha up to $4.8 million in funding over 12 years, dependent upon meeting hiring and capital expenditure milestones, as well as a training grant of over $360,000 over a two- to three-year period. The Company will also receive a local incentive investment of up to $4.6 million over four years.

“The pandemic has highlighted the importance of science and innovation to keep us healthy,” said Governor Roy Cooper. “Companies like Taysha Gene Therapies continue to expand in North Carolina because we have the scientists, skilled workers and climate for innovation they need to tackle health care’s toughest challenges.”

“Taysha’s decision to expand to Durham continues to support our city’s reputation as a leading hub for technology, innovation and life sciences,” said City of Durham’s Mayor Steve Schewel. “Companies globally are seeing Durham as a thriving location to attract talent and grow their business.”

The following North Carolina organizations were instrumental in Taysha’s expansion in North Carolina: North Carolina Department of Commerce, the Economic Development Partnership of N.C., the North Carolina General Assembly, the North Carolina Community College System, the North Carolina Biotechnology Center, Durham County, the Greater Durham Chamber of Commerce and Duke Energy.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the potential of our product candidates and our plans to establish a commercial-scale cGMP manufacturing facility to provide preclinical, clinical and commercial supply. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings, including in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, which is available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005961/en/

Company Contact:

Kimberly Lee, D.O.

Taysha Gene Therapies

[email protected]

Media Contact:

Carolyn Hawley

Canale Communications

[email protected]

KEYWORDS: North Carolina Texas United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Genetics Health

MEDIA:

Logo

Spruce Biosciences Added to Russell 2000®, 3000® and Microcap® Indexes

SAN FRANCISCO–(BUSINESS WIRE)–Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need, today announced that it will be added to the Russell 2000®, 3000® and Microcap® Indexes effective December 21, 2020, following Russell’s quarterly additions of select initial public offerings.

“Our inclusion in the Russell indexes reflects the meaningful progress we continue to make toward our goal of changing the treatment paradigm for people living with congenital adrenal hyperplasia,” said Richard King, Chief Executive Officer of Spruce Biosciences. “We believe that this important milestone will increase the overall awareness and visibility of our company within the investment community and broadens our institutional shareholder base.”

Russell indexes are part of FTSE Russell, a leading global index provider. FTSE Russell determines membership for its Russell Indexes primarily by objective, market-capitalization rankings and style attributes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell’s U.S. indexes.

The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000®, representing approximately 10 percent of the total market capitalization of that index. Membership in the Russell 2000® Index includes automatic inclusion in the appropriate growth and style indexes. The Russell Microcap® Index measures the performance of the microcap segment of the U.S. equity market.

About FTSE Russell

FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $16 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives. FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group.

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH). Classic CAH is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “will”, “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce’s business in general, the impact of the COVID-19 pandemic, and the other risks described in Spruce’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005837/en/

Media

Will Zasadny

Canale Communications

(619) 961-8848

[email protected]

[email protected]

Investors

Thomas Hoffmann

Solebury Trout

(646) 378-2931

[email protected]

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Finance Health Professional Services Pharmaceutical

MEDIA:

Logo

Repare Therapeutics Added to the NASDAQ Biotechnology Index

CAMBRIDGE, Mass. & MONTREAL–(BUSINESS WIRE)–
Repare Therapeutics, Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI). Repare’s addition to the NBI will become effective prior to market open on Monday, December 21, 2020.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market and meet minimum market value and share volume requirements, among other criteria.

For more information about the NASDAQ Biotechnology Index, including eligibility criteria, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-state precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor, as well as CCNE1-SL inhibitor and Polθ inhibitor programs. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics, Inc.

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the discovery of potential product candidates using SNIPRx® platform; and the clinical development of the Company’s pipeline and its research and development programs, including the anticipated timing of its clinical trials of RP-3500 and RP-6306; and the development of preclinical assets pursuant to the Company’s collaboration with Bristol Myers Squibb. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic on the Company’s business, clinical trials and financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2020 filed with the Securities and Exchange Commission (the “SEC”) on November 12, 2020, and its subsequent filings with the SEC. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005830/en/

Repare Contact:

Steve Forte

Chief Financial Officer

Repare Therapeutics, Inc.

[email protected]

Investors:

Kimberly Minarovich

Argot Partners

[email protected]

Media:

David Rosen

Argot Partners

[email protected]

212-600-1902

KEYWORDS: Massachusetts United States North America Canada

INDUSTRY KEYWORDS: Biotechnology Health Genetics Pharmaceutical Oncology

MEDIA:

Posted on December 17, 2020 4:08 pm

Palantir Announces Inaugural Live Demo Day on January 26, 2021

Palantir Announces Inaugural Live Demo Day on January 26, 2021

DENVER–(BUSINESS WIRE)–
Palantir Technologies (NYSE:PLTR) today announced that it will hold its inaugural “Live Demo Day” on Tuesday, January 26, 2021 at 4:30pm ET.

Palantir’s product demos will include its Foundry, Gotham, and Apollo platforms. Product leads will show the latest releases of each platform, and describe the upcoming research & development roadmap for 2021. Palantir will cover examples of its commercial and government work.

Advance registration is required, and is available at https://palantir.events/livedemoday. For any questions regarding the event, please email [email protected].

About Palantir Technologies Inc.

Palantir Technologies is a software company that builds enterprise data platforms for use by organizations with complex and sensitive data environments. From building safer cars and planes, to discovering new drugs and combating terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data. Additional information is available at https://www.palantir.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006092/en/

Lisa Gordon

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Networks Data Management Other Technology Technology Software

MEDIA:

Logo

Datadog Releases Capabilities to Correlate User Sessions with Backend Application Traces

Datadog’s new two-way correlation eliminates blind spots for on-call engineering teams by connecting traditionally disparate performance data

NEW YORK–(BUSINESS WIRE)–Datadog, Inc. (NASDAQ: DDOG), the monitoring and security platform for cloud applications, today announced new capabilities connecting user experience data with application traces, bridging the gap between frontend and backend performance monitoring. This new capability enables on-call engineering teams to pinpoint the root cause of issues impacting customer experience on mobile and web-based applications to backend services.

Traditional Real User Monitoring (RUM) and Application Performance Monitoring (APM) solutions are siloed, requiring separate workflows to troubleshoot across the stack. This makes connecting user experience data from browsers and mobile applications with backend traces, metrics, and logs a complex and tedious task. These manual correlation efforts slow down on-call engineering teams when trying to remediate issues, as they struggle to pinpoint which part of the application stack is responsible for revenue impacting incidents. Datadog’s automatic two-way correlation for frontend user sessions in RUM and backend traces in APM eliminates these blind spots, allowing on-call teams to quickly identify root causes and thus maintain robust user-experience on browser and mobile applications.

“Typically, frontend and backend engineers use their own, siloed monitoring solutions and rarely even look at the same signals and metrics. Very often, issues can arise anywhere in the stack and propagate in every direction,” said Renaud Boutet, Vice President of Product, Datadog. “By automatically connecting user journeys that start on the frontend with requests made to backend services, Datadog enables organizations to significantly reduce MTTD and MTTR for incidents.”

“Our DevOps and SRE teams use the Datadog RUM to APM connection to visualize the full user journey and pinpoint the exact source of an errant or slow customer request within their stack,” said Ronni Persson, Engineering Manager, Web Platform Team, SeatGeek. “The automatic correlation of the frontend and backend enables our teams to communicate using the same language when resolving errors across the stack.”

Datadog’s new APM and RUM capabilities automatically correlate critical application performance data, providing teams with:

• Full-Stack Correlation: connecting every user request to all backend services to cut down MTTD and MTTR with a unified view across the application stack
• Frontend/Backend Comparison: comparing frontend and backend durations on every request, enabling engineering teams to identify and optimize slow user experiences
• Trace Search and Analytics by User Journey Tags: slicing and dicing backend traces by location, device, operating system, and more to provide context for impacted customers

For more information on end-to-end monitoring, please visit: www.datadoghq.com/blog/unify-apm-rum-datadog

About Datadog

Datadog is the monitoring and security platform for cloud applications. Our SaaS platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide unified, real-time observability of our customers’ entire technology stack. Datadog is used by organizations of all sizes and across a wide range of industries to enable digital transformation and cloud migration, drive collaboration among development, operations, security and business teams, accelerate time to market for applications, reduce time to problem resolution, secure applications and infrastructure, understand user behavior and track key business metrics.

Forward-Looking Statements

This press release may include certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including those risks detailed under the caption “Risk Factors” and elsewhere in our Securities and Exchange Commission filings and reports, including the Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2020, as well as future filings and reports by us. Except as required by law, we undertake no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005815/en/

For Datadog

Martin Bergman

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Data Management Security Technology Mobile/Wireless Software Networks Internet

MEDIA:

Posted on December 17, 2020 4:08 pm

Intersect ENT to Present at the 39th Annual J.P. Morgan Healthcare Conference

Intersect ENT to Present at the 39^th Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif.–(BUSINESS WIRE)–
Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that management will participate in the 39^th Annual J.P. Morgan Healthcare Conference. Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will present at 5:00 p.m. ET / 2:00 p.m. PT on Tuesday, January 12, 2021.

A live webcast of the presentation can be accessed by visiting the “Investor Relations” page of the Company’s website at www.intersectENT.com. A replay will be available on the Company’s website following the event.

About Intersect ENT

Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care. The Company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. In addition, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings that complement the Company’s PROPEL^® and SINUVA^® sinus implants and extend its geographic reach.

For additional information on the Company or the products including risks and benefits please visit www.IntersectENT.com. For more information about PROPEL^® (mometasone furoate) sinus implants and SINUVA^® (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com.

Intersect ENT^®, PROPEL^® and SINUVA^® are registered trademarks of Intersect ENT, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006091/en/

Intersect ENT, Inc.

Randy Meier, 650-641-2105

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Medical Devices

MEDIA:

Logo

Ark Restaurants Announces Conference Call

NEW YORK–(BUSINESS WIRE)–
Ark Restaurants Corp. (NASDAQ:ARKR) will hold a conference call for investors and analysts to discuss financial results for the fourth quarter and fiscal year ended October 3, 2020 on Tuesday, December 22, 2020 at 11:00 a.m. Eastern Time.

The dial-in numbers to participate in the conference call are:

Toll-Free – 1-877-407-4018

Toll/International – 1-201-689-8471

The Company will also broadcast its conference call over the Internet. To access the broadcast, please visit http://www.viavid.net. A replay of the broadcast will be available within three hours of the call, and will be available until Tuesday December 29, 2020, 11:59pm. The dial-in telephone numbers for the replay are:

Toll-Free – 1-844-512-2921

Toll/International – 1-412-317-6671

Replay Pin Number – 13714428

Ark Restaurants owns and operates 20 restaurants and bars, 17 fast food concepts and catering operations primarily in New York City, Florida, Washington, D.C., Las Vegas, NV and the gulf coast of Alabama. Five restaurants are located in New York City, two are located in Washington, D.C., five are located in Las Vegas, Nevada, three are located in Atlantic City, New Jersey, three are located on the east coast of Florida and two are located on the Gulf Coast of Alabama. The Las Vegas operations include four restaurants within the New York-New York Hotel & Casino Resort and operation of the hotel’s room service, banquet facilities, employee dining room and six food court concepts; and one restaurant within the Planet Hollywood Resort and Casino. In Atlantic City, New Jersey, the Company operates a restaurant and a bar in the Resorts Atlantic City Hotel and Casino and a restaurant in the Tropicana Hotel and Casino. The operations at the Foxwoods Resort Casino consist of one fast food concept. The Florida operations include the Rustic Inn in Dania Beach, Shuckers, located in Jensen Beach, JB’s on the Beach in Deerfield Beach and the operation of four fast food facilities in Tampa, Florida and six fast food facilities in Hollywood, Florida, each at a Hard Rock Hotel and Casino operated by the Seminole Indian Tribe at these locations. In Alabama, the Company operates two Original Oyster Houses, one in Gulf Shores, Alabama and one in Spanish Fort, Alabama.

Except for historical information, this news release contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve unknown risks, and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. Important factors that might cause such differences are discussed in the Company’s filings with the Securities and Exchange Commission. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results could differ materially from those anticipated in these forward-looking statements, if new information becomes available in the future.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201217006053/en/

Anthony Sirica

(212) 206-8800

[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Retail Restaurant/Bar Food/Beverage

MEDIA: